Innodia: Surrounding diabetes

In a slight twist on the typical NRDO business model, Innodia Inc. has no internal research capabilities of its own, relying on a network of academic and corporate partnerships to in-license Type II diabetes candidates that are within 18 months of an IND. Its strategy is to develop an array of oral small

Read the full 533 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE